Holen Sie sich die Stockscreener-App
3.9377
2.57%
0.0477
Schlusskurs vom Vortag:
$3.89
Offen:
$3.48
24-Stunden-Volumen:
1.41M
Relative Volume:
1.16
Marktkapitalisierung:
$327.79M
Einnahmen:
$13.86M
Nettoeinkommen (Verlust:
$-81.74M
KGV:
-3.0206
EPS:
-1.3036
Netto-Cashflow:
$-66.98M
1W Leistung:
+6.40%
1M Leistung:
+6.97%
6M Leistung:
+166.00%
1J Leistung:
+118.03%
1-Tages-Spanne:
$3.132
$4.12
1-Wochen-Bereich:
$3.132
$4.15
52-Wochen-Spanne:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.93 | 324.46M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
523.27 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.70 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.85 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.78 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.14 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology stock falls 7% despite positive trial data By Investing.com - Investing.com Canada
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer - TradingView
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study - marketscreener.com
Pyxis Oncology Reports Promising MICVO Phase 1 Results - TipRanks
Pyxis Oncology reports 36% cORR, 6.2‑month mPFS and 79% 12‑month OS probability for MICVO in 2L+ HNSCC - TradingView
Head and neck cancer drug from Pyxis Oncology (PYXS) shows tumor responses ahead of 500-patient trial - Stock Titan
A cancer treatment showed disease control in 94% of trial patients. Pyxis plans a roughly 500-patient trial. - Stock Titan
Pyxis Oncology Announces Positive Updated Data from Phase 1 - GlobeNewswire
symbol__ Stock Quote Price and Forecast - cnn.com
Pyxis Oncology Shares Gain 9.25% After HoursPyxis Oncology (NASDAQ:PYXS) - Benzinga
Pyxis Oncology to present clinical data on cancer therapy By Investing.com - Investing.com India
Pyxis Oncology to present clinical data on cancer therapy - Investing.com
Updated cancer-drug data will be presented Sept. 9. A Memorial Sloan Kettering expert will join Pyxis Oncology. - Stock Titan
Pyxis Oncology Names Thomas Civik CEO and Chairman Ahead of MICVO Milestones - citybiz.co
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board - Oncodaily
Pyxis Oncology Names Thomas Civik CEO, Board Chairman - marketscreener.com
Pyxis Oncology, Inc. Announces Board Changes - marketscreener.com
Pyxis Oncology, Inc. Announces Appointment of Thomas Civik to Chief Executive Officer, Effective September 4, 2026 - marketscreener.com
Pyxis Oncology Elevates Thomas Civik to Permanent CEO - TipRanks
Pyxis Oncology names Thomas Civik as permanent CEO and chairman By Investing.com - Investing.com Canada
Pyxis Oncology names Thomas Civik as permanent CEO and chairman - Investing.com
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
Pyxis Oncology Appoints Thomas Civik CEO and Chairman as John Flavin Becomes Lead Independent Director - Quiver Quantitative
New CEO-chair steps in at Pyxis Oncology (PYXS) ahead of 2026 cancer drug data - Stock Titan
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - Stock Titan
PYXS Rallies As Pyxis Oncology Extends Cash Runway To 2027 - timothysykes.com
PYXS Jumps As Pyxis Oncology Extends Cash Runway, Eyes MICVO Data - timothysykes.com
Pyxis Oncology stock gains on MICVO conference catalysts - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Peer Comparison – Compare with Others - Value Research
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
PYXS Stock Price, Quote & Chart - ChartMill
Pyxis Oncology to Participate in Upcoming Investor Conferences - Yahoo Finance
Pyxis Oncology Inc (PYXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology (PYXS) Holds Steady at $3.01 as Consolidation TightensWyckoff Accumulation - vinanet.vn
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - AlphaStreet
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):